SCHEMBL23744796

SCHEMBL23744796

CCOc1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.53
ALDH1A1 P00352 3/20 0.53
TP53 P04637 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
BACE1 P56817 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NQO1 P15559 1/20 0.47
LMNA P02545 1/20 0.46
GAA P10253 2/20 0.46
ACACB O00763 9/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
APP P05067 1/20 0.43
ALOX15 P16050 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
SNCA P37840 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246615 0.83 MAPT (0.49) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL21659256 0.83 KMT2A (0.46) ACACBKMT2ACHRNB2CHRNA4
SCHEMBL5274705 0.83 MAPT (0.49) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL23744808 0.81 HTR3E (0.53) MAPTRAB9AGAAKMT2AMEN1
SCHEMBL21963784 0.79 CHRNB2 (0.66) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL23732273 0.79 CHRNB2 (0.66) MAPTALDH1A1TP53NPC1RAB9A
Hydrochloric Acid SCHEMBL23199740 0.78 CHRNB2 (0.68) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL10268319 0.77 KDM4E (0.49) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL11503962 0.76 MAPT (0.65) MAPTALDH1A1TP53NPC1RAB9A
SCHEMBL3586400 0.76 HRH3 (0.68) MAPTALDH1A1GAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 MAPT 1187/4885ALDH1A1 1378/4885TP53 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.